Binimetinib Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 15 mg
Reference Brands: Mektovi (USA/EU)
Category: Oncology Cancer Care
Binimetinib is a MEK inhibitor used in targeted cancer therapy. It works by blocking MEK1/MEK2 enzymes in the MAPK pathway, helping slow down the growth of cancer cells. It is commonly used along with encorafenib for cancers with BRAF mutation. Binimetinib is available in Tablets and strengths such as 15 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Binimetinib is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Binimetinib can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Binimetinib is used to treat certain cancers, including unresectable or metastatic melanoma with BRAF V600E or V600K mutations, and in combination with other drugs for some non-small cell lung cancers with BRAF mutations.
Binimetinib is a small-molecule MEK1/2 inhibitor that blocks the activity of MEK enzymes in the MAPK/ERK signaling pathway, which helps prevent cancer cells from multiplying.
The trade name is Mektovi.
It is manufactured and marketed by Array BioPharma Inc., a subsidiary of Pfizer, under the trade name Mektovi.
The generic name is binimetinib.
The brand name is Mektovi.
Binimetinib tablets are produced in pharmaceutical manufacturing facilities in the United States under standard regulatory practices.
Related Products
Gemtuzumab Ozogamicin
Strength:
4.5 mg
Form: Injection
Reference Brands: Mylotarg (USA)
View Details
Tafasitamab‑Cxix
Strength:
200 mg
Form: Injection
Reference Brands: Monjuvi (USA), Minjuvi (EU)
View Details
Dordaviprone Hydrochloride
Strength:
125 mg
Form: Capsules
Reference Brands: Modeyso (USA)
View Details
Quick Response Guaranteed | Verified Suppliers
